Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Cancer
|
October 6, 2021
Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study
Daniel E Meyers, Benjamin S Meyers, Timothy M Chisamore, et al.
JCO Oncology Practice
|
June 13, 2022
Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?
Kristin Wright, Daniel E Meyers, Timothy M Chisamore, et al.
Current Oncology (Toronto, Ont.)
|
October 27, 2022
Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab
Siddhartha Goutam, Igor Stukalin, Benjamin Ewanchuk, et al.
Cancers
|
June 20, 2018
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
Ahmed A Mostafa, Daniel E Meyers, Chandini M Thirukkumaran, et al.
JAMA Network Open
|
January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
Sarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Frontiers in Immunology
|
July 3, 2024
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer
Annalise G Abbott, Daniel E Meyers, Golpira Elmi-Assadzadeh, et al.
Cancer Medicine
|
March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
Michael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.
Cancers
|
November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
Daniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
JAMA Network Open
|
December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
Alexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.
BMC Medical Education
|
August 29, 2020
Oncology education for family medicine residents: a national needs assessment survey
Steven M Yip, Daniel E Meyers, Jeff Sisler, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Cancer
|
October 6, 2021
Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study
Daniel E Meyers, Benjamin S Meyers, Timothy M Chisamore, et al.
JCO Oncology Practice
|
June 13, 2022
Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?
Kristin Wright, Daniel E Meyers, Timothy M Chisamore, et al.
Current Oncology (Toronto, Ont.)
|
October 27, 2022
Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab
Siddhartha Goutam, Igor Stukalin, Benjamin Ewanchuk, et al.
Cancers
|
June 20, 2018
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
Ahmed A Mostafa, Daniel E Meyers, Chandini M Thirukkumaran, et al.
JAMA Network Open
|
January 18, 2024
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
Sarah Cook, Vanessa Samuel, Daniel E Meyers, et al.
Frontiers in Immunology
|
July 3, 2024
Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer
Annalise G Abbott, Daniel E Meyers, Golpira Elmi-Assadzadeh, et al.
Cancer Medicine
|
March 16, 2021
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
Michael S Sander, Igor Stukalin, Isabelle A Vallerand, et al.
Cancers
|
November 6, 2019
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
Daniel E Meyers, Igor Stukalin, Isabelle A Vallerand, et al.
JAMA Network Open
|
December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
Alexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.
BMC Medical Education
|
August 29, 2020
Oncology education for family medicine residents: a national needs assessment survey
Steven M Yip, Daniel E Meyers, Jeff Sisler, et al.
Page
of 3